Likewise, given that the presence of inflammation differentiates NASH from steatosis, further studies comparing serum levels of ASC, IL-18, and Gal-3 in patients with NASH to those with steatosis may help validate these potential biomarkers for NASH. Here, LGALS3 is linked to metabolic dysfunction-associated steatohepatitis.